Related references
Note: Only part of the references are listed.Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
Giuseppe Di Lorenzo et al.
BJU INTERNATIONAL (2011)
Cabazitaxel for castration-resistant prostate cancer Reply
Johann Sebastian de Bono et al.
LANCET (2011)
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer
Stephanie Jeske et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2011)
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
M. M. Regan et al.
ANNALS OF ONCOLOGY (2010)
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
Jean-Christophe Eymard et al.
BJU INTERNATIONAL (2010)
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
Yohann Loriot et al.
EUROPEAN JOURNAL OF CANCER (2010)
Docetaxel Rechallenge in Castration-Resistant Prostate Cancer: Scientific Legitimacy of Common Clinical Practice
Carlo Buonerba et al.
EUROPEAN UROLOGY (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer
A. Sella et al.
ONCOLOGY (2009)
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life
Hatem A. Azim et al.
ANTI-CANCER DRUGS (2008)
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
Mari Nakabayashi et al.
BJU INTERNATIONAL (2008)
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
Robert W. Ross et al.
CANCER (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Taxane refractory prostate cancer
Paul Mathew et al.
JOURNAL OF UROLOGY (2007)
Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
William K. Oh et al.
CANCER (2007)
A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer
William Berry et al.
CLINICAL GENITOURINARY CANCER (2006)
Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer
A Cabrespine et al.
UROLOGY (2006)
Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy resistant hormone-refractory prostate cancer: A pilot study
S Urakami et al.
UROLOGY (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma - Cancer and leukemia group B 99813
WK Oh et al.
CANCER (2003)
Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer
S Urakami et al.
JOURNAL OF UROLOGY (2002)
Androgen receptor as a target in androgen-independent prostate cancer
SP Balk
UROLOGY (2002)
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
CN Papandreou et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The binding conformation of Taxol in β-tubulin:: A model based on electron crystallographic density
JP Snyder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
